Login / Signup

Clinical and laboratory features of anti-MAG neuropathy without monoclonal gammopathy.

Elba Pascual-GoñiLorena Martín-AguilarCinta LleixàLaura Martínez-MartínezManuel J Simón-TaleroJordi Díaz-ManeraElena Cortés-VicenteRicard Rojas-GarcíaEsther MogaCándido JuárezIsabel IllaLuis Antonio Querol-Gutiérrez
Published in: Scientific reports (2019)
Antibodies against myelin-associated glycoprotein (MAG) almost invariably appear in the context of an IgM monoclonal gammopathy associated neuropathy. Very few cases of anti-MAG neuropathy lacking IgM-monoclonal gammopathy have been reported. We investigated the presence of anti-MAG antibodies in 69 patients fulfilling diagnostic criteria for CIDP. Anti-MAG antibodies were tested by ELISA and confirmed by immunohistochemistry. We identified four (5.8%) anti-MAG positive patients without detectable IgM-monoclonal gammopathy. In two of them, IgM-monoclonal gammopathy was detected at 3 and 4-year follow-up coinciding with an increase in anti-MAG antibodies titers. In conclusion, anti-MAG antibody testing should be considered in chronic demyelinating neuropathies, even if IgM-monoclonal gammopathy is not detectable.
Keyphrases
  • end stage renal disease
  • multiple myeloma
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • mass spectrometry
  • patient reported outcomes
  • white matter
  • patient reported